ヒト肝臓モデルの世界市場：製品タイプ別、用途別、最終用途別、地域別の分析、規模、動向、予測（～2030年）

ヒト肝臓モデルは、ヒト肝臓を科学的・技術的に表現したもので、さまざまな生理的・病理的状態における肝臓の構造、機能、挙動を研究するために用いられます。これらのモデルは、創薬、毒性試験、疾患モデリング、再生医療、個別化医療における用途に極めて重要です。従来の肝臓研究は、動物モデルや2次元細胞培養に大きく依存していましたが、これらのアプローチではヒトの肝臓の生理機能を正確に再現できないことが多いです。世界のヒト肝臓モデルの市場規模は、2024年に16億4,000万米ドルであり、2030年までに38億1,000万米ドルに達すると予測されます。

世界のヒト肝臓モデル市場は主に、非アルコール性脂肪性肝疾患（NAFLD/MASLD）、アルコール性肝疾患（ALD）、ウイルス性肝炎、肝がんなどの肝疾患の有病率の増加によって牽引されています。このような需要の増加は、3Dバイオプリンティング、臓器チッププラットフォーム、オルガノイドなどの臓器プリンティング技術の進歩によってさらに促進され、従来の2D細胞培養や動物モデルと比較して、より生理学的に適切で予測可能なヒト肝臓モデルの作成が可能になります。さらに、倫理的な懸念や、ヒトにおける医薬品の安全性や有効性の予測にしばしば不正確さをもたらす固有の種の差から、動物実験への依存を減らすことが重視されており、ヒト由来の肝臓モデルの採用を大幅に後押ししています。最後に、肝臓がんやその他の肝臓疾患に対する治療薬に対する需要の高まりは、従来の創薬に伴う高いコストと失敗率もあり、より効率的な薬剤スクリーニング、毒性試験、個別化医療アプローチ に向け、製薬企業やバイオテクノロジー企業がこれらの先進のモデルに投資する動機付けとなっています。世界のヒト肝臓モデルの市場金額は、2025年～2030年の予測期間にCAGRで15.03%の成長が見込まれます。

当レポートでは、世界のヒト肝臓モデル市場について調査分析し、成長促進要因と課題、市場動向、競合情勢などの情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 イントロダクション

• ヒト肝臓モデル：概要
  • ヒト肝臓モデルのイントロダクション
  • ヒト肝臓モデルの利点
• ヒト肝臓モデルのセグメンテーション：概要
  • ヒト肝臓モデルのセグメンテーション

第3章 世界市場の分析

• 世界のヒト肝臓モデル市場：分析
  • 世界のヒト肝臓モデル市場：概要
  • 世界のヒト肝臓モデルの市場規模
  • 世界のヒト肝臓モデル市場：製品タイプ別（2Dヒト肝臓モデル、3Dヒト肝臓モデル）
  • 世界のヒト肝臓モデル市場：用途別（ADME研究、毒性試験、疾患モデリング、その他）
  • 世界のヒト肝臓モデル市場：最終用途別（製薬・バイオテクノロジー企業、開発業務受託機関、学術・研究機関）
  • 世界のヒト肝臓モデル市場：地域別（北米、欧州、アジア太平洋、その他の地域）
• 世界のヒト肝臓モデル市場：製品タイプの分析
  • 世界のヒト肝臓モデル市場：製品タイプ別、概要
  • 世界の2Dヒト肝臓モデルの市場規模
  • 世界の2Dヒト肝臓モデル市場：製品タイプ別（細胞株、初代ヒト肝細胞）
  • 世界の細胞株2Dヒト肝臓モデルの市場規模
  • 世界の初代ヒト肝細胞2Dヒト肝臓モデルの市場規模
  • 世界の3Dヒト肝臓モデルの市場規模
  • 世界の3Dヒト肝臓モデル市場：製品タイプ別（肝臓チップ、オルガノイド、スフェロイド、3Dバイオプリント組織）
  • 世界の肝臓チップ3Dヒト肝臓モデルの市場規模
  • 世界のオルガノイド3Dヒト肝臓モデルの市場規模
  • 世界のスフェロイド3Dヒト肝臓モデルの市場規模
  • 世界の3Dバイオプリント組織ヒト肝臓モデルの市場規模
• 世界のヒト肝臓モデル市場：用途の分析
  • 世界のヒト肝臓モデル市場：用途別、概要
  • 世界のADME研究向けヒト肝臓モデルの市場規模
  • 世界の毒性試験向けヒト肝臓モデルの市場規模
  • 世界の疾患モデリング向けヒト肝臓モデルの市場規模
  • 世界のその他のヒト肝臓モデルの市場規模
• 世界のヒト肝臓モデル市場：最終用途の分析
  • 世界のヒト肝臓モデル市場：最終用途別、概要
  • 世界の製薬・バイオテクノロジー企業向けヒト肝臓モデルの市場規模
  • 世界の開発業務受託機関向けヒト肝臓モデルの市場規模
  • 世界の学術・研究機関向けヒト肝臓モデルの市場規模

第4章 地域市場の分析

• 北米のヒト肝臓モデル市場：分析
  • 北米のヒト肝臓モデル市場：概要
  • 北米のヒト肝臓モデルの市場規模
  • 北米のヒト肝臓モデル市場：地域別（米国、カナダ、メキシコ）
  • 米国のヒト肝臓モデルの市場規模
  • カナダのヒト肝臓モデルの市場規模
  • メキシコのヒト肝臓モデルの市場規模
• 欧州のヒト肝臓モデル市場：分析
  • 欧州のヒト肝臓モデル市場：概要
  • 欧州のヒト肝臓モデルの市場規模
  • 欧州のヒト肝臓モデル市場：地域別（ドイツ、英国、フランス、イタリア、スペイン、その他の欧州）
  • ドイツのヒト肝臓モデルの市場規模
  • 英国のヒト肝臓モデルの市場規模
  • フランスのヒト肝臓モデルの市場規模
  • イタリアのヒト肝臓モデルの市場規模
  • スペインのヒト肝臓モデルの市場規模
  • その他の欧州のヒト肝臓モデルの市場規模
• アジア太平洋のヒト肝臓モデル市場：分析
  • アジア太平洋のヒト肝臓モデル市場：概要
  • アジア太平洋のヒト肝臓モデルの市場規模
  • アジア太平洋のヒト肝臓モデル市場（中国、日本、インド、韓国、その他のアジア太平洋）
  • 中国のヒト肝臓モデルの市場規模
  • 日本のヒト肝臓モデルの市場規模
  • インドのヒト肝臓モデルの市場規模
  • 韓国のヒト肝臓モデルの市場規模
  • その他のアジア太平洋のヒト肝臓モデルの市場規模
• その他の地域のヒト肝臓モデル市場：分析
  • その他の地域の肝臓モデル市場：概要
  • その他の地域のヒト肝臓モデルの市場規模

第5章 市場力学

• 成長促進要因
  • 肝疾患の有病率の増加
  • 動物実験の代替手段への需要の高まり
  • 個別化医療への注目の高まり
  • 肝臓研究への投資の増加
  • 薬物毒性の早期診断へのニーズの高まり
• 課題
  • 肝臓モデルの高いコスト
  • 熟練した専門家の不足
• 市場動向
  • AIと機械学習の統合
  • 臓器プリンティングと組織工学技術の進歩
  • 2Dから先進の3D、ex vivoモデルへの移行
  • ハイブリッドモデルとin silicoモデルの台頭

第6章 競合情勢

• 世界のヒト肝臓モデル市場の企業：競合情勢
  • 世界のヒト肝臓モデル市場の企業：概要
• 世界のヒト肝臓モデル市場の企業：近年の発展

第7章 企業プロファイル

• Corning Incorporated
• Organovo Holdings Inc.
• InSphero AG
• BioIVT LLC
• Emulate Inc.
• MatTek (The BICO Group)
• MIMETAS
• CN Bio Innovations Ltd.
• Cyfuse Biomedical K.K.
• PhoenixBio Co., Ltd.
• STEMCELL Technologies
• Pandorum Technologies Pvt. Ltd.
• Kirkstall Ltd.

List of Figures

• Figure 1: Benefits of Human Liver Model
• Figure 2: Human Liver Model Segmentation
• Figure 3: Global Human Liver Model Market by Value; 2020-2024 (US$ Billion)
• Figure 4: Global Human Liver Model Market by Value; 2025-2030 (US$ Billion)
• Figure 5: Global Human Liver Model Market by Product Type; 2024 (Percentage, %)
• Figure 6: Global Human Liver Model Market by Application; 2024 (Percentage, %)
• Figure 7: Global Human Liver Model Market by End-use; 2024 (Percentage, %)
• Figure 8: Global Human Liver Model Market by Region; 2024 (Percentage, %)
• Figure 9: Global 2D Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 10: Global 2D Human Liver Model Market by Value; 2025-2030 (US$ Billion)
• Figure 11: Global 2D Human Liver Model Market by Product Type; 2024 (Percentage, %)
• Figure 12: Global Cell Lines 2D Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 13: Global Cell Lines 2D Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 14: Global Primary Human Hepatocytes 2D Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 15: Global Primary Human Hepatocytes 2D Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 16: Global 3D Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 17: Global 3D Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 18: Global Human Liver Model Market by Product Type; 2024 (Percentage, %)
• Figure 19: Global Liver-on-a-chip 3D Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 20: Global Liver-on-a-chip 3D Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 21: Global Organoids 3D Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 22: Global Organoids 3D Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 23: Global Spheroids 3D Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 24: Global Spheroids 3D Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 25: Global 3D Bio printed Tissues Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 26: Global 3D Bio printed Tissues Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 27: Global ADME Studies Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 28: Global ADME Studies Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 29: Global Toxicology Testing Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 30: Global Toxicology Testing Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 31: Global Disease Modeling Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 32: Global Disease Modeling Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 33: Global Others Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 34: Global Others Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 35: Global Pharmaceutical & Biotechnology Companies Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 36: Global Pharmaceutical & Biotechnology Companies Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 37: Global Contract Research Organizations Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 38: Global Contract Research Organizations Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 39: Global Academic and Research Institutes Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 40: Global Academic and Research Institutes Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 41: North America Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 42: North America Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 43: North America Human Liver Model Market by Region; 2024 (Percentage, %)
• Figure 44: The US Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 45: The US Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 46: Canada Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 47: Canada Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 48: Mexico Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 49: Mexico Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 50: Europe Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 51: Europe Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 52: Europe Human Liver Model Market by Region; 2024 (Percentage, %)
• Figure 53: Germany Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 54: Germany Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 55: United Kingdom Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 56: United Kingdom Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 57: France Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 58: France Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 59: Italy Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 60: Italy Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 61: Spain Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 62: Spain Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 63: Rest of Europe Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 64: Rest of Europe Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 65: Asia Pacific Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 66: Asia Pacific Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 67: Asia Pacific Human Liver Model Market by Region; 2024 (Percentage, %)
• Figure 68: China Human Liver Model Market by Value, 2020-2024 (US$ Million)
• Figure 69: China Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 70: Japan Human Liver Model Market by Value, 2020-2024 (US$ Million)
• Figure 71: Japan Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 72: India Human Liver Model Market by Value, 2020-2024 (US$ Million)
• Figure 73: India Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 74: South Korea Human Liver Model Market by Value, 2020-2024 (US$ Million)
• Figure 75: South Korea Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 76: Rest of Asia Pacific Human Liver Model Market by Value, 2020-2024 (US$ Million)
• Figure 77: Rest of Asia Pacific Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 78: Rest of the World Human Liver Model Market by Value; 2020-2024 (US$ Million)
• Figure 79: Rest of the World Human Liver Model Market by Value; 2025-2030 (US$ Million)
• Figure 80: Global Artificial Intelligence (AI) in Healthcare Market; 2021-2030 (US$ Billion)
• Figure 81: Corning Incorporated Net Sales by Segments; 2024 (Percentage, %)

The human liver model is a scientific and technological representation of the human liver that is used to study its structure, function, and behavior in various physiological and pathological conditions. These models are crucial for applications in drug discovery, toxicology testing, disease modeling, regenerative medicine, and personalized healthcare. Traditional liver research relied heavily on animal models and 2D cell cultures, but these approaches often fall short of accurately replicating human liver physiology. The global human liver model market value in 2024 stood at US$1.64 billion, and is projected to reach US$3.81 billion by 2030.

The global human liver model market is primarily driven by the increasing prevalence of liver diseases such as non-alcoholic fatty liver disease (NAFLD/MASLD), alcoholic liver disease (ALD), viral hepatitis, and liver cancer. This growing demand is further propelled by advancements in organ printing technologies like 3D bioprinting, organ-on-a-chip platforms, and organoids, which allow for the creation of more physiologically relevant and predictive human liver models compared to traditional 2D cell cultures or animal models. Additionally, a strong emphasis on reducing reliance on animal testing due to ethical concerns and the inherent species differences that often lead to inaccurate drug safety and efficacy predictions in humans, significantly boosts the adoption of human-derived liver models. Finally, the increasing demand for therapeutic drugs for liver cancer and other liver conditions, coupled with the high costs and failure rates associated with conventional drug discovery, incentivizes pharmaceutical and biotechnology companies to invest in these advanced models for more efficient drug screening, toxicity testing, and personalized medicine approaches. The global human liver model market value is projected to grow at a CAGR of 15.03%, during the forecast period of 2025-2030.

Market Segmentation Analysis:

By Product Type: According to the report, based on product type, the global human liver model market can be divided into two segments: 2D human liver model and 3D human liver model. 2D human liver model segment is further segmented based on product as cell lines and primary human hepatocytes and 3D human liver model segment is bifurcated as liver-on-a-chip, organoids, spheroids and 3D bio printed tissues. 2D human liver model segment acquired majority of share in the market in 2024 primarily due to its cost-effectiveness, simplicity, and well-established protocols. Many researchers still rely on 2D models for high-throughput screening and initial drug toxicity testing, where their efficiency and reliability provided a practical solution despite their limitations in fully replicating in vivo conditions. However, the 3D human liver model segment is expected to grow the fastest because these models offer significantly enhanced physiological relevance, better mimicking the complex architecture, cell-cell interactions, and metabolic functions of a real human liver compared to 2D cultures. This improved accuracy leads to more reliable predictions in drug discovery, toxicity testing, and disease modeling, reducing late-stage drug failures and the need for animal testing. As technologies like 3D bioprinting and organ-on-a-chip mature and become more accessible, their capacity for higher throughput and scalability is also increasing, making them increasingly attractive for pharmaceutical and biotechnology companies seeking more predictive and human-relevant research tools.

By Application: According to the report, based on application, the global human liver model market can be divided into four segments: ADME Studies, toxicology testing, disease modeling and others. ADME segment acquired majority of share in the market in 2024 because these studies are critical and often mandated early steps in drug development. By using human liver models for ADME studies, pharmaceutical companies can more accurately simulate human physiological conditions, allowing them to filter out unsuitable drug candidates earlier in the costly and time-consuming drug discovery pipeline, thereby saving significant resources and accelerating drug development. Meanwhile, the toxicology testing segment is expected to grow the fastest during the forecasted period, driven by rising concern about drug-induced liver injury (DILI) and other organ toxicities, leading to increased demand for robust preclinical models that can accurately predict adverse effects in humans. Secondly, stricter regulatory guidelines worldwide are pushing pharmaceutical companies to conduct more comprehensive and reliable toxicity assessments earlier in the drug development pipeline. Finally, the limitations and ethical concerns associated with traditional animal testing are driving a shift towards more human-relevant in vitro models, like the advanced 3D liver models, for more accurate and predictive toxicology screens.

By End-use: According to the report, the global human liver model market is bifurcated into three types of end-uses: pharmaceutical & biotechnology companies, contract research organizations, and academic and research institutes. Pharmaceutical & biotechnology companies segment acquired the majority share in the global human liver model market in 2024 because they are the primary drivers of drug discovery and development. These companies heavily rely on human liver models for crucial preclinical studies, including assessing drug metabolism (ADME), evaluating drug-drug interactions, and, most importantly, identifying potential hepatotoxicity. The ability of these models to more accurately predict human physiological responses, thereby reducing costly failures in later clinical trial stages, makes them indispensable tools for pharmaceutical and biotech firms striving for efficient and safer drug development. However, CROs are projected for the fastest growth as pharmaceutical and biotech companies increasingly outsource R&D to leverage specialized expertise, advanced technologies, and cost efficiencies. This allows them to accelerate drug development and manage resources more effectively without the need for significant in-house investment in complex human liver model platforms.

By Region: The report provides insight into the human liver model market based on the geographical operations, namely, North America, Europe, Asia Pacific and Rest of the World. North America human liver model market enjoyed the highest market share in 2024 due to its robust healthcare infrastructure, significant R&D expenditure by pharmaceutical and biotechnology companies, and a favorable regulatory environment supporting advanced preclinical testing. Meanwhile, Asia Pacific is projected for the fastest growth driven by increasing investments in medical research, a burgeoning biotech industry, rising prevalence of liver diseases, and improving healthcare infrastructure across the region.

Global Human liver model Market Dynamics:

Growth Drivers: One of the most important factors driving the growth of the global human liver model market is is the increasing prevalence of liver diseases worldwide. Conditions like non-alcoholic fatty liver disease (NAFLD/MASLD), alcoholic liver disease (ALD), viral hepatitis, and liver cancer are on the rise globally due to lifestyle changes and other factors. This escalating disease burden creates an urgent and growing demand for more accurate, human-relevant research tools to better understand disease mechanisms, develop effective therapies, and conduct efficient drug discovery and toxicity testing. Other factors driving the growth of global human liver model market include growing demand for alternatives to animal testing, increasing focus on personalized medicine, growing investment in liver research, the growing need for early drug toxicity diagnosis etc.

Challenges: One significant challenge faced by the global human liver model market is the high cost and technical complexity associated with developing and maintaining advanced 3D models. While these models offer superior physiological relevance, their creation often requires specialized equipment, skilled personnel, and significant financial investment. This complexity can limit their accessibility and scalability, particularly for smaller research institutions or companies, hindering widespread adoption despite their clear advantages over traditional 2D systems.

Trends: A major trend that will further drive the growth of the global human liver model market is the advancement and increasing adoption of 3D bioprinting and organ-on-a-chip technologies. These innovations are enabling the creation of more sophisticated, physiologically relevant, and high-throughput human liver models that better mimic in-vivo conditions. This improved accuracy leads to more reliable data in drug discovery, toxicity testing, and disease modeling, ultimately accelerating the development of safer and more effective treatments while reducing reliance on traditional, less predictive methods. The market is also projected to grow at a fast pace during the forecast period, due to various other latest trends such as integration of AI and machine learning, advancements in organ printing and tissue engineering technologies, shift from 2D to advanced 3D and ex vivo models, rise of hybrid and in silico models etc.

Competitive Landscape and Recent Developments:

The global human liver model market currently presents a moderately fragmented competitive landscape, although it is showing clear signs of moving towards consolidation, particularly within its more technologically advanced segments. The fragmentation stems from rapid pace of innovation in tissue engineering, microfluidics, and stem cell biology continually giving rise to new biotech startups. Regional market differences and the significant contributions from academic research also contribute to this distributed competitive environment. However, consolidation is evident in the dominance of a few key players in the cutting-edge 3D model segments (like InSphero, CN Bio Innovations, and Emulate), who possess strong patent portfolios and are often preferred partners for large pharmaceutical companies. This trend is further driven by strategic mergers and acquisitions (M&A) and increasing partnerships, as larger entities seek to integrate specialized technologies and expertise. Key players of global human liver model market are:

Organovo Holdings

InSphero

BioIVT LLC

Emulate Inc.

MatTek

Mimetas

CN Bio Innovations Ltd.

Cyfuse Biomedical KK

Corning Incorporated

Pheonix Bio

Stemcell Technologies

Pandorum Technologies

Kirkstall Ltd

The key players are constantly investing in strategic initiatives, such as adoption of new technologies, introducing their products to emerging markets and more, to maintain a competitive edge in this market. For instance, In February 2025, CN Bio launched the PhysioMimix(R) DILI assay kit: Human 24, an all-in-one kit providing rapid access to their FDA-recognized human Drug-Induced Liver Injury (DILI) assay. This kit streamlines workflows and allows users to assess up to eight conditions simultaneously, leveraging their highly functional and metabolically active liver microphysiological system (MPS).

Table of Contents

1. Executive Summary

2. Introduction

• 2.1 Human Liver Model: An Overview
  • 2.1.1 Introduction to Human Liver Model
  • 2.1.2 Benefits of Human Liver Model
• 2.2 Human Liver Model Segmentation: An Overview
  • 2.2.1 Human Liver Model Segmentation

3. Global Market Analysis

• 3.1 Global Human Liver Model Market: An Analysis
  • 3.1.1 Global Human Liver Model Market: An Overview
  • 3.1.2 Global Human Liver Model Market by Value
  • 3.1.3 Global Human Liver Model Market by Product Type (2D Human Liver Model and 3D Human Liver Model)
  • 3.1.4 Global Human Liver Model Market by Application (ADME Studies, Toxicology Testing, Disease Modeling and Others)
  • 3.1.5 Global Human Liver Model Market by End-use (Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic and Research Institutes)
  • 3.1.6 Global Human Liver Model Market by Region (North America, Europe, Asia Pacific and Rest of the World)
• 3.2 Global Human Liver Model Market: Product Type Analysis
  • 3.2.1 Global Human Liver Model Market by Product Type: An Overview
  • 3.2.2 Global 2D Human Liver Model Market by Value
  • 3.2.3 Global 2D Human Liver Model Market by Product Type (Cell Lines and Primary Human Hepatocytes)
  • 3.2.4 Global Cell Lines 2D Human Liver Model Market by Value
  • 3.2.5 Global Primary Human Hepatocytes 2D Human Liver Model Market by Value
  • 3.2.6 Global 3D Human Liver Model Market by Value
  • 3.2.7 Global 3D Human Liver Model Market by Product Type (Liver-on-a-chip, Organoids, Spheroids and 3D bio printed tissues)
  • 3.2.8 Global Liver-on-a-chip 3D Human Liver Model Market by Value
  • 3.2.9 Global Organoids 3D Human Liver Model Market by Value
  • 3.2.10 Global Spheroids 3D Human Liver Model Market by Value
  • 3.2.11 Global 3D Bio printed Tissues Human Liver Model Market by Value
• 3.3 Global Human Liver Model Market: Application Analysis
  • 3.3.1 Global Human Liver Model Market by Application: An Overview
  • 3.3.2 Global ADME Studies Human Liver Model Market by Value
  • 3.3.3 Global Toxicology Testing Human Liver Model Market by Value
  • 3.3.4 Global Disease Modeling Human Liver Model Market by Value
  • 3.3.5 Global Others Human Liver Model Market by Value
• 3.4 Global Human Liver Model Market: End-use Analysis
  • 3.4.1 Global Human Liver Model Market by End-use: An Overview
  • 3.4.2 Global Pharmaceutical & Biotechnology Companies Human Liver Model Market by Value
  • 3.4.3 Global Contract Research Organizations Human Liver Model Market by Value
  • 3.4.4 Global Academic and Research Institutes Human Liver Model Market by Value

4. Regional Market Analysis

• 4.1 North America Human Liver Model Market: An Analysis
  • 4.1.1 North America Human Liver Model Market: An Overview
  • 4.1.2 North America Human Liver Model Market by Value
  • 4.1.3 North America Human Liver Model Market by Region (The US, Canada and Mexico)
  • 4.1.4 The US Human Liver Model Market by Value
  • 4.1.5 Canada Human Liver Model Market by Value
  • 4.1.6 Mexico Human Liver Model Market by Value
• 4.2 Europe Human Liver Model Market: An Analysis
  • 4.2.1 Europe Human Liver Model Market: An Overview
  • 4.2.2 Europe Human Liver Model Market by Value
  • 4.2.3 Europe Human Liver Model Market by Region (Germany, UK, France, Italy, Spain and Rest of Europe)
  • 4.2.4 Germany Human Liver Model Market by Value
  • 4.2.5 United Kingdom Human Liver Model Market by Value
  • 4.2.6 France Human Liver Model Market by Value
  • 4.2.7 Italy Human Liver Model Market by Value
  • 4.2.8 Spain Human Liver Model Market by Value
  • 4.2.9 Rest of Europe Human Liver Model Market by Value
• 4.3 Asia Pacific Human Liver Model Market: An Analysis
  • 4.3.1 Asia Pacific Human Liver Model Market: An Overview
  • 4.3.2 Asia Pacific Human Liver Model Market by Value
  • 4.3.3 Asia Pacific Human Liver Model Market by Region (China, Japan, India, South Korea and Rest of Asia Pacific)
  • 4.3.4 China Human Liver Model Market by Value
  • 4.3.5 Japan Human Liver Model Market by Value
  • 4.3.6 India Human Liver Model Market by Value
  • 4.3.7 South Korea Human Liver Model Market by Value
  • 4.3.8 Rest of Asia Pacific Human Liver Model Market by Value
• 4.4 Rest of the World Human Liver Model Market: An Analysis
  • 4.4.1 Rest of the World Human Liver Model Market: An Overview
  • 4.4.2 Rest of the World Human Liver Model Market by Value

5. Market Dynamics

• 5.1 Growth Drivers
  • 5.1.1 Increasing Prevalence of Liver Diseases
  • 5.1.2 Growing Demand for Alternatives to Animal Testing
  • 5.1.3 Increasing Focus on Personalized Medicine
  • 5.1.4 Growing Investment in Liver Research
  • 5.1.5 The Growing Need for Early Drug Toxicity Diagnosis
• 5.2 Challenges
  • 5.2.1 High Cost of Liver Models
  • 5.2.2 Dearth of Skilled Professionals
• 5.3 Market Trends
  • 5.3.1 Integration of AI and Machine Learning
  • 5.3.2 Advancements in Organ Printing and Tissue Engineering Technologies
  • 5.3.3 Shift from 2D to Advanced 3D and Ex Vivo Models
  • 5.3.4 Rise of Hybrid and In Silico Models

6. Competitive Landscape

• 6.1 Global Human Liver Model Market Players: Competitive Landscape
  • 6.1.1 Global Human Liver Model Market Players: An Overview
• 6.2 Global Human Liver Model Market Players: Recent Developments

7. Company Profiles

• 7.1 Corning Incorporated
  • 7.1.1 Business Overview
  • 7.1.2 Operating Segments
  • 7.1.3 Business Strategies
• 7.2 Organovo Holdings Inc.
  • 7.2.1 Business Overview
  • 7.2.2 Business Strategies
• 7.3 InSphero AG
  • 7.3.1 Business Overview
  • 7.3.2 Business Strategies
• 7.4 BioIVT LLC
  • 7.4.1 Business Overview
  • 7.4.2 Business Strategies
• 7.5 Emulate Inc.
  • 7.5.1 Business Overview
  • 7.5.2 Business Strategies
• 7.6 MatTek (The BICO Group)
  • 7.6.1 Business Overview
  • 7.6.2 Business Strategies
• 7.7 MIMETAS
  • 7.7.1 Business Overview
  • 7.7.2 Business Strategies
• 7.8 CN Bio Innovations Ltd.
  • 7.8.1 Business Overview
  • 7.8.2 Business Strategies
• 7.9 Cyfuse Biomedical K.K.
  • 7.9.1 Business Overview
  • 7.9.2 Business Strategies
• 7.10 PhoenixBio Co., Ltd.
  • 7.10.1 Business Overview
  • 7.10.2 Business Strategies
• 7.11 STEMCELL Technologies
  • 7.11.1 Business Overview
  • 7.11.2 Business Strategies
• 7.12 Pandorum Technologies Pvt. Ltd.
  • 7.12.1 Business Overview
• 7.13 Kirkstall Ltd.
  • 7.13.1 Business Overview